Thu, November 10, 2022
Wed, November 9, 2022
Tue, November 8, 2022
Mon, November 7, 2022

Gregory Renza Maintained (ADCT) at Buy with Decreased Target to $20 on, Nov 9th, 2022

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-decreased-target-to-20-on-nov-9th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication
Gregory Renza of RBC Capital, Maintained "ADC Therapeutics SA" (ADCT) at Buy with Decreased Target from $25 to $20 on, Nov 9th, 2022.

Gregory has made no other calls on ADCT in the last 4 months.



There are 3 other peers that have a rating on ADCT. Out of the 3 peers that are also analyzing ADCT, 1 agrees with Gregory's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Downgraded from Buy to Hold and Decreased Target to $11 on, Friday, September 9th, 2022


These are the ratings of the 2 analyists that currently disagree with Gregory


  • Brian Cheng of "JP Morgan" Initiated at Buy and Held Target at $5 on, Wednesday, September 21st, 2022
  • Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $21 on, Monday, September 19th, 2022